Pulmonary Function Testing (PFT) is an integral part of respiratory disease diagnosis and management. However, understanding and interpreting these tests can be challenging due to their complexity. This guide aims to elucidate the intricacies of PFT interpretation for healthcare professionals.
Key components of PFT include spirometry, lung volumes, and diffusion capacity. Spirometry measures the speed of air movement in the lungs, providing information on airway obstruction. Lung volumes assess the amount of air in different phases of the respiratory cycle, revealing restrictive patterns. Diffusion capacity evaluates how well oxygen moves from the lungs into the blood.
Spirometry interpretation involves three key parameters: Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the FEV1/FVC ratio. A reduced FEV1/FVC ratio suggests obstructive disease, while a reduced FVC with a normal or increased FEV1/FVC ratio indicates restrictive disease.
Restrictive diseases reduce all lung volumes, while obstructive diseases may increase residual volume and total lung capacity. Key parameters include Total Lung Capacity (TLC), Vital Capacity (VC), and Residual Volume (RV). A reduced VC or TLC suggests restrictive disease, and an increased RV/TLC ratio suggests air trapping typical of obstructive disease.
The Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) measures gas transfer across the alveolar-capillary membrane. Reduced DLCO can indicate interstitial lung disease, emphysema, or pulmonary vascular disease.
Interpreting PFTs is a complex task requiring a strong understanding of respiratory physiology and pathology. However, with a systematic approach to each component of the PFT and a clear understanding of the disease patterns they represent, healthcare professionals can effectively use these vital tools to diagnose and manage respiratory diseases.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation